Circular RNAs in Drug-Induced Cardiotoxicity: Roles, Mechanisms, and Therapeutic Potential.
4 affiliations
- 1China State Institute of Pharmaceutical Industry, Shanghai Innostar Bio-Technology Co. Ltd., Shanghai, China.
- 2College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, China.
- 3InnoStar Bio-tech Nantong Co. Ltd., Nantong, Jiangsu, China.
- 4Yangtze Delta Drug Advanced Research Institute, Yangtze Delta Pharmaceutical College, Nantong, Jiangsu, China.
Abstract
Drug-induced cardiotoxicity (DIC) remains a major challenge in drug development and clinical practice, often resulting in treatment interruption, drug attrition, and adverse cardiovascular outcomes. DIC has been associated with a wide range of therapeutic agents, including anthracyclines, HER2-targeted therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors, and other cardiotoxic drugs. Circular RNAs (circRNAs) have attracted increasing attention as stable and versatile regulatory RNAs involved in cardiovascular injury. This review summarizes the biogenesis and functional mechanisms of circRNAs, their pathological roles in DIC, biomarker potential, therapeutic implications, and translational challenges. CircRNAs regulate gene expression through diverse mechanisms, including miRNA sequestration, interactions with RNA-binding proteins, transcriptional regulation, modulation of alternative splicing, and, in some cases, peptide translation. These regulatory functions have been implicated in apoptosis, oxidative stress, mitochondrial dysfunction, inflammatory signaling, pyroptosis, and cardiac remodeling during DIC. Emerging evidence suggests that circRNAs may serve as candidate molecular markers and potential therapeutic targets for DIC. However, the current evidence is derived predominantly from cellular and animal models, with doxorubicin-induced cardiotoxicity accounting for a substantial proportion of available studies. Clinical validation, particularly in well-characterized patient cohorts and across different drug classes, remains limited. Overall, further efforts are needed to establish standardized circRNA detection and quantification methods, validate their functional roles, conduct prospective clinical studies, and determine their incremental value in combination with established cardiac biomarkers before circRNA-based approaches can be translated into clinical management of DIC.
Related
- Circular RNAs in tumor biology and immunology: molecular mechanisms and therapeutic implications
- Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
- Targeting circular RNAs to overcome therapeutic resistance in liver cancer: from mechanisms to clinical prospects
- The m6A methyltransferase METTL3 in intervertebral disc degeneration: from molecular mechanisms to therapeutic potential
- Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)
BibTeX
@article{leng2026circular,
title = {{Circular RNAs in Drug-Induced Cardiotoxicity: Roles, Mechanisms, and Therapeutic Potential.}},
author = {KeXin Leng and Zixuan Yang and Lei Shi and Zhimin Sun and Mengyun Gu and Naping Tang},
journal = {Journal of biochemical and molecular toxicology},
year = {2026},
month = oct,
doi = {10.1002/jbt.71143},
url = {https://europepmc.org/article/MED/42900022},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Circular RNAs in Drug-Induced Cardiotoxicity: Roles, Mechanisms, and Therapeutic Potential.
AU - KeXin Leng
AU - Zixuan Yang
AU - Lei Shi
AU - Zhimin Sun
AU - Mengyun Gu
AU - Naping Tang
PY - 2026
DA - 2026/10/30
JO - Journal of biochemical and molecular toxicology
DO - 10.1002/jbt.71143
UR - https://europepmc.org/article/MED/42900022
AB - Drug-induced cardiotoxicity (DIC) remains a major challenge in drug development and clinical practice, often resulting in treatment interruption, drug attrition, and adverse cardiovascular outcomes. DIC has been associated with a wide range of therapeutic agents, including anthracyclines, HER2-targeted therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors, and other cardiotoxic drugs. Circular RNAs (circRNAs) have attracted increasing attention as stable and versatile regulatory RNAs involved in cardiovascular injury. This review summarizes the biogenesis and functional mechanisms of circRNAs, their pathological roles in DIC, biomarker potential, therapeutic implications, and translational challenges. CircRNAs regulate gene expression through diverse mechanisms, including miRNA sequestration, interactions with RNA-binding proteins, transcriptional regulation, modulation of alternative splicing, and, in some cases, peptide translation. These regulatory functions have been implicated in apoptosis, oxidative stress, mitochondrial dysfunction, inflammatory signaling, pyroptosis, and cardiac remodeling during DIC. Emerging evidence suggests that circRNAs may serve as candidate molecular markers and potential therapeutic targets for DIC. However, the current evidence is derived predominantly from cellular and animal models, with doxorubicin-induced cardiotoxicity accounting for a substantial proportion of available studies. Clinical validation, particularly in well-characterized patient cohorts and across different drug classes, remains limited. Overall, further efforts are needed to establish standardized circRNA detection and quantification methods, validate their functional roles, conduct prospective clinical studies, and determine their incremental value in combination with established cardiac biomarkers before circRNA-based approaches can be translated into clinical management of DIC.
SN - 1095-6670
SN - 1099-0461
ER -